Oramed Pharmaceuticals Inc. (ORMP.TA)
Tel Aviv · ILA · Healthcare · Biotechnology
ILA 1,284.00 (-0.62%) as of
Key statistics
- Market cap
- 534.11M
- P/E (TTM)
- 0.98
- EPS (TTM)
- 13.15
- Dividend yield
- 6.10%
- 52-week range
- 7.00 – 1,742.00
- Beta
- 1.28
- Profit margin
- 0.00%
- Volume
- 1.30k
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.